Welcome Snackers, today’s snack will cover the market developments of Shape Robotics, DFDS, Roblon A/S & Hansa Biopharma.
Today’s Market Movements
Denmark:
OMX:C25 (-1.1%)
Sweden:
OMX:S30 (-0.73%)
Norway:
OBX:OSL (0.51%)
S&P 500 (0.21%)
Nasdaq (-0.1%)
Today’s European markets reacted to news from China which again suggests its economy is decelerating. China’s retail sales rose 2.5% in August after rising 8.5% in July; this figure was expected to be around 7%. The figure is due to a combination of Covid-19 and flooding. The industrial production numbers also showed signs of a slowdown, rising 5.3% against July’s increase of 6.4% and expectations of 5.8%. Retail sales told a similar story in the US as they fell unexpectedly by 1.1%. The mood has changed from fears of runaway inflation to fears that the global economy is decelerating.
Today’s snacks
A.P. Moller – Maersk presents its debut, introduction to the share, event tomorrow with HC Andersen Capital tomorrow at 14:00 CET. Link:https://lnkd.in/exw3XkYJ
Shape Robotics saw its share price increase 20.2% today after featuring in a finans.dk article. The article highlights Shape Robotics’ large project in Romania which the company said could generate revenues of up to DKK 420m over the next two years. The project involves setting up 1,175 Smart Labs in the country. Full delivery of the planned 61 Smart Labs in 2021 would generate revenues of approx. DKK 18m, surpassing the year-end guidance of DKK 14-17m. For further detail watch their latest event: https://lnkd.in/ePgXYNRm
DFDS has today announced its acquisition of the Danish freight forwarding company ICT Logistics, after owning 19.9% since 2003. The full ownership will strengthen DFDS’ Eastern European position, allowing it to develop its business in the Baltics and surrounding countries. The acquisition complements its Baltic ferry route network. Read the full press release here: https://lnkd.in/e-SHkjUc.
Roblon A/S today published its interim report for Q3 where they outlined a negative guidance revision. The company has endured disruption relating to the Covid-19 pandemic, particularly in Brazil. Resultant project delays have created difficulty in predicting revenues. The share price fell 6.4% today but CEO Lars Østergaard expects a more positive 2022. Find out why on Sept 21 when Roblon discusses its report with HC Andersen Capital.
Hansa Biopharma shares fell 6.9% today in a highly volatile week for the biopharma sector. CEO Søren Tulstrup presented its main imlifidase product this week at a series of investment conferences. Link: https://lnkd.in/edWtJXVz
Disclaimer: HC Andersen Capital receives payment from the companies for a #DigitalIR agreement.
Author: Philip Coombes
